Immunocore
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 days.
- Its last 3 Sell calls were followed by a 7% average decline over the next quarter.
- Recent price momentum is -29.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 15.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 98.7% | Better than 99% |
| Operating margin | -11.3% | Better than 14% |
| Net margin | -8.9% | Better than 16% |
| Return on equity | -9.6% | Better than 20% |
| Return on invested capital | -4.8% | Better than 22% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -28.4% | Better than 19% |
| 6-month return | -8.4% | Better than 42% |
| 12-month return (ex latest month) | -18.4% | Better than 16% |
| Distance below 52-week high | 35.1% | Better than 34% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.0x | Better than 81% |
| Debt to assets | 40.9% | Better than 26% |
| Interest coverage | -0.6x | Better than 23% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 60.0% | Better than 36% |
| Upside to average target | 115.1% | Better than 86% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 26.63
- Open
- 26.37
- Day range
- 25.61 - 26.82
- Avg price
- 26.36
- Volume
- 546.18K
- Turnover
- 14.40M
- Turnover ratei
- 1.19%
- Volume ratioi
- 1.77
- Amplitudei
- 4.53%
- 52-week rangei
- 25.61 - 40.71
Valuation
- P/Ei
- -37.20
- P/E (TTM)i
- -41.27
- P/Bi
- 3.25
- EPSi
- -0.71
- Book value / shi
- 8.12
- Net profit
- -36.69M
- Net assets
- 419.70M
Share structure
- Market cap
- 1.36B
- Float capi
- 1.21B
- Shares out
- 51.68M
- Float sharesi
- 45.99M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-02-05
35.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-20.20M net over the window
Short interest
- Shares short
- 7.79M
- % of floati
- 15.13%
- Days to coveri
- 14.21
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Immunocore (IMCR)?
Immunocore last traded at 26.41. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Immunocore's market cap?
About 1.36B.
What is the P/E ratio of Immunocore?
The trailing twelve-month P/E is -41.27. The Valuation tab shows it against the stock's own five-year range.
Does Immunocore pay a dividend?
Immunocore does not currently pay a regular dividend.
Is Immunocore a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 56.80, which implies 115.1% upside from the current price. This is not investment advice.
What is Immunocore's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Immunocore a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.
Immunocore discussion 0 comments